PT-141 (Bremelanotide)

PT-141, also called bremelanotide, is a melanocortin receptor agonist studied for low sexual desire. Unlike the familiar erectile dysfunction tablets it does not act on blood flow — it acts centrally, on the brain pathways involved in wanting sex. It is approved in the United States for one specific diagnosis in premenopausal women, and in Australia it is prescription-only and compounded rather than registered.

What PT-141 is

PT-141 is a synthetic peptide, known generically as bremelanotide. It is a cyclic seven-amino-acid molecule derived from research into analogues of alpha-melanocyte-stimulating hormone (α-MSH) — the same line of work that produced the melanotan compounds. It has been studied for sexual dysfunction, and specifically for the desire component of it.

In the United States it is approved and marketed as Vyleesi, a self-administered injection, for one narrowly defined diagnosis: acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval is real and it rests on a genuine phase 3 programme, which puts PT-141 ahead of most compounds discussed in this space.

It is also widely discussed and sold in contexts that have nothing to do with that approval — for men, for postmenopausal women, and as nasal sprays. Those uses are not what was tested, and the gap between the two is the most important thing on this page after the mechanism.

In Australia bremelanotide is not a registered medicine. Where it is used, it is a compounded preparation made by a compounding pharmacy against a prescription for an individual patient.

How it works

The useful distinction is between blood flow and desire. They are separate problems with separate biology, and almost all the confusion around PT-141 comes from conflating them.

The familiar erectile dysfunction tablets work on plumbing. PDE5 inhibitors such as sildenafil and tadalafil block an enzyme that breaks down a signalling molecule in the smooth muscle of the penis, so that when arousal already exists the vascular response is amplified and sustained. What they emphatically do not do is create desire. If arousal is not happening, a PDE5 inhibitor has nothing to amplify.

PT-141 works upstream, in the brain. It is an agonist at melanocortin receptors — a family of five, with jobs ranging from pigmentation (MC1R) to appetite and sexual behaviour (MC4R). Bremelanotide is non-selective but its relevant activity is at MC4R, expressed densely in hypothalamic regions long associated with sexual motivation in animal work. Activating those receptors appears to influence downstream dopaminergic signalling in circuits involved in motivation and reward.

In plain terms: PDE5 inhibitors act on the response; bremelanotide is aimed at the wanting. That is why one is not a substitute for the other, and why matching the treatment to the actual complaint matters more than which compound is more fashionable.

The mechanism also explains the side effects rather than being unrelated to them. Melanocortin receptors sit in circuits affecting nausea and autonomic tone, which is why nausea and transient blood-pressure changes are common rather than rare — and activity at MC1R is why repeated exposure can darken skin.

What the human evidence actually shows

The premenopausal HSDD evidence is the real evidence. Two identically designed phase 3 trials, known as the RECONNECT studies, enrolled more than 1,200 premenopausal women with acquired, generalised HSDD and ran over roughly six months. Bremelanotide produced statistically significant improvements against placebo on both co-primary endpoints: a validated measure of sexual desire, and a measure of the distress associated with low desire. Those results supported US FDA approval in 2019.

The size of the benefit was modest, and one thing did not change. The improvements, while statistically significant, were small on average, and the number of satisfying sexual events — arguably the outcome a person actually cares about — did not separate meaningfully from placebo. Placebo response in this field is substantial. A treatment can be genuinely better than placebo and still be a modest intervention, and that is the fairest reading here.

Dropout from side effects was not trivial. Nausea was common enough that a meaningful proportion of participants discontinued because of it — which belongs in any honest summary of efficacy, because a benefit you stop taking is not a benefit.

There is no confirmatory phase 3 evidence in men. Bremelanotide was originally developed for erectile dysfunction, including as an intranasal product, and that programme was discontinued in the mid-2000s after increases in blood pressure were observed. Later work in men exists but no confirmatory programme was completed and no regulator has approved it for men anywhere. Use in men is therefore an extrapolation, not an evidence-based indication.

Postmenopausal women were not the studied population either. The approval is specific to premenopausal women, and HSDD after menopause has different contributors and evidence.

Nasal sprays are not the studied product. The original intranasal formulation was abandoned. Compounded nasal preparations sold today have not been through the trials that supported the injectable product, and results from one route of administration do not transfer automatically to another.

Regulatory positions and product availability in this area change. Anything you read about bremelanotide's status — including here — is worth confirming with your prescriber or pharmacist against current sources.

Regulatory status in Australia

Bremelanotide is a Schedule 4 (Prescription Only) substance in Australia, and there is no ARTG-registered bremelanotide product. Vyleesi, the approved US product, is not registered here.

Where an Australian patient receives it, it is typically a compounded preparation — prepared by a compounding pharmacy for an individual patient on prescription. Compounding is lawful and long-established, but it is a different regulatory pathway from registration, and the differences are practical:

• The preparation has not been evaluated by the TGA for safety, efficacy or quality.
• There is no TGA-approved Product Information setting out approved indications, contraindications and interactions.
• Batch consistency depends entirely on the compounding pharmacy's own quality systems.
• Supply without a prescription — from overseas websites, "research chemical" vendors or anyone selling direct to consumers — is outside the lawful pathway and carries no assurance of identity, sterility or purity.

One further note. PT-141 is chemically related to the melanotan compounds, which the TGA has publicly warned about as unapproved tanning products. They are not the same substance and are not interchangeable, but the family resemblance is why pigmentation appears in the side-effect list.

Advertising prescription-only medicines directly to consumers is restricted in Australia. A clinic can discuss options with you inside a consultation; seeing a compound like this promoted publicly with claimed benefits is a signal worth noticing. Our guide to compounded versus registered medicines and the overview of whether peptides are legal in Australia go into the framework in more depth.

Who it is being studied for — and who it is not for

The population studied and approved is narrow: premenopausal women with acquired, generalised HSDD. Each word in that phrase is doing work. Acquired means desire was previously present and has fallen. Generalised means it is not confined to one partner or one setting. And HSDD requires that the low desire causes personal distress and is not better explained by another condition, a relationship problem, a medicine or a substance.

That last exclusion is where most of the clinical value sits, because low desire very often has a cause that is treatable in its own right. Depression and anxiety, SSRIs and other medications, thyroid disease, iron deficiency, chronic pain, sleep debt, alcohol, perimenopausal hormonal change, low testosterone, and relationship distress are all common contributors. A practitioner who reaches for a compounded peptide before any of that has been examined has skipped the part of the consultation that actually changes outcomes. Our overview of sexual health care sets out what a thorough assessment covers, and the guide to testosterone therapy covers one of the causes most often raised.

Situations where a practitioner would be cautious or would decline include uncontrolled high blood pressure, known cardiovascular disease, pregnancy and breastfeeding, and a history of significant pigmentation concerns or melanoma. It was studied for intermittent, occasion-based use rather than for continuous use, which is a further reason it does not suit an open-ended arrangement.

Risks and considerations

With no registered Australian product there is no TGA-evaluated safety document. The side-effect picture below comes from the trial programme and the approved US labelling.

Nausea is the dominant side effect. It affected a large share of participants in the trials, was sometimes significant, and was a leading reason people stopped. Vomiting, flushing, headache and injection-site reactions are also common.

Blood pressure and heart rate change transiently. Studies observed a temporary rise in blood pressure and a fall in heart rate in the hours after administration. This is why it is not appropriate for people with uncontrolled hypertension or clinically significant cardiovascular disease, and why cardiovascular assessment is not an optional formality before use.

Skin darkening can occur and may not fully reverse. Focal hyperpigmentation — face, gums, breasts — has been reported with repeated use, and appears more likely with more frequent exposure and in people with darker skin. In some cases it did not completely resolve after stopping.

Compounded product quality varies. What is in the vial depends on the pharmacy, and grey-market or nasal products bought online carry no assurance at all. It is also an injectable, which brings technique, sterility and sharps-handling considerations of its own.

Any unexpected or concerning symptom — particularly chest pain, severe headache or a significant blood pressure change — should go to a treating practitioner promptly.

What to ask a doctor

• What do you think is actually causing my low desire, and how did you reach that?
• Have the common contributors — mood, medications, thyroid, iron, hormones, sleep, relationship factors — been assessed and addressed first?
• Is what you are proposing registered or compounded? If compounded, which pharmacy prepares it and what quality assurance do they hold?
• Has this been studied in people like me, for this specific problem? What did those studies actually measure?
• Is my blood pressure and cardiovascular health safe for this, and what monitoring do you want?
• What is the realistic size of the benefit, how will we know whether it has worked, and what is the stopping rule if it has not?
• What are the risks of skin pigmentation, and are they reversible?
• What does the full course cost, including consultations and follow-up?
• Would a psychologist or sex therapist add something alongside, or instead of, a prescription?

FAQ

Is PT-141 approved in Australia? No. Bremelanotide is Schedule 4 (Prescription Only) and there is no ARTG-registered product. The US-approved product Vyleesi is not registered here. Any Australian supply would be a compounded preparation against an individual prescription.

Does it work like Viagra? No, and this is the most useful thing to understand about it. PDE5 inhibitors such as sildenafil act on blood flow and amplify a vascular response that arousal has already started. Bremelanotide acts on melanocortin receptors in the brain and is aimed at desire itself. They address different complaints and are not substitutes for one another.

Is there good evidence it works in men? No confirmatory phase 3 evidence exists in men, and no regulator has approved it for men. The original development programme in erectile dysfunction was discontinued after blood pressure increases were observed. Use in men is an extrapolation from a mechanism and from trials conducted in a different population.

Is a nasal spray the same thing? Not in evidence terms. The trials that supported approval used a subcutaneous injection. The intranasal programme was abandoned. Compounded nasal preparations sold today have not been through that testing, and route of administration changes absorption, peak levels and therefore both effect and side effects.

Should I look for a clinic that offers it? Start with the problem rather than the compound. Low desire has a long list of causes that are more common, more treatable and cheaper to address than an unregistered peptide, and the assessment that identifies them is the part worth paying for. If a compounded treatment is genuinely appropriate after a proper consultation, it will still be available then. You can compare doctor-led clinics once you know what you are actually looking for.